Archive | June, 2018

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

http://graphics-remarkable.com/wp-json/oembed/1.0/embed?url=http://graphics-remarkable.com/virtual-tours/454-arnold-way/ Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Rayno BioBeat #4 2018: ASCO Biotech Momentum Continues with M&A Theme…Updates 6/29

http://weband.co.uk/?p=5066 Momentous  Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]

Continue Reading 0

Rayno Life Science Portfolio Flash Update: Roche and FMI Merger; Update with XBI breakout

http://pykmax.com/video/eric-beaty-plays-legacy/ Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50 in the pre-market. We added FMI to our top picks on […]

Continue Reading 0

Mid-Cap Biotech Watch List: Updated 6/12/18 After Huge ASCO Rally

  Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of the best ASCO stock rallies on record in 2018 focusing on small and […]

Continue Reading 0

Biotech Mid-Cap Momentum Leaders and Laggards…Update…gene editing

Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60,  EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine. After the close biotech […]

Continue Reading 0

ASCO 2018 Biotech Rally Part 2 : Traders Take Profits on Nice Gains…Updates

ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD,  IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum easing from profit taking and digestion of news. […]

Continue Reading 0

ASCO 2018 Biotech Rally : Teetering at the Top But a Leading Sector

ASCO 2018 Biotech Rally: Biotechs, Techs, and Semis Lead Market Higher Mid-Caps show huge gains but with high volatility. FBT at 142.91, IBB lagging at $110.52, XBI leading at $97.77 IWC Micro-Cap ETF breaking out up 11% YTD. Healthcare (XLV) comes to life lately up over 2% YTD. As we predicted in early May Mid-Cap […]

Continue Reading 0

Mid-Cap Biotechs Lead the Market: Pre-ASCO Scoreboard…Updates 6/4/18

6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%.  Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news. However there will be some clear cut winners after the Meeting. […]

Continue Reading 0